NewAmsterdam Pharma Company N.V.NAMSNASDAQ

Revenue (LTM)

$23M

-50.6% YoY

Net Income (LTM)

$-204M

+15.6% YoY

Free Cash Flow

$-148M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	103	14↓86.3%	46↑223.4%	23↓50.6%
Gross Profit	0	103	14↓86.3%	46↑223.4%	22↓50.7%
Operating Income	-35	-4↑89.8%	-183↓5043.9%	-176↑3.6%	-226↓28.0%
Net Income	-42	-23↑45.8%	-177↓681.7%	-242↓36.5%	-204↑15.6%
EBITDA	-41	-22↑46.0%	-177↓691.7%	-241↓36.5%	-242↓0.3%
EPS Diluted	-3.34	-1.19↑64.4%	-2.15↓80.7%	-2.56↓19.1%	-1.75↑31.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	60	468↑674.6%	340↓27.2%	772↑126.7%	490↓36.5%
Total Current Assets	67	478↑613.9%	347↓27.4%	863↑149.0%	676↓21.7%
Total Assets	68	478↑603.8%	347↓27.5%	865↑149.1%	769↓11.0%
Total Current Liabilities	11	36↑220.9%	50↑38.4%	107↑114.3%	86↓19.8%
Total Liabilities	11	48↑326.2%	59↑21.2%	107↑82.5%	86↓19.9%
Total Equity	57	430↑659.5%	288↓32.9%	758↑162.7%	683↓9.8%
Total Debt	0	0↓32.4%	0↓52.4%	0↑646.7%	0↓54.9%
Net Debt	-60	-468↓676.8%	-340↑27.2%	-771↓126.6%	-490↑36.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-30	11↑136.1%	-141↓1424.1%	-159↓12.3%	-148↑6.8%
Capital Expenditure	-0	-0↓820.8%	-0↑89.1%	-1↓2700.0%	-0↑63.4%
Free Cash Flow	-30	10↑135.4%	-141↓1452.4%	-159↓12.7%	-148↑7.0%
Stock-Based Comp	1	4↑230.9%	25↑496.8%	34↑36.8%	59↑76.8%
Net Change in Cash	50	408↑707.4%	-127↓131.2%	431↑438.9%	-280↓165.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance